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Abstract 
ALCAM (Activated Leukocyte Cell Adhesion 
Molecule), also known as CD166 (cluster of 
differentiation 166), is a member of a subfamily of 
immunoglobulin receptors with five 
immunoglobulin-like domains (VVC2C2C2) in the 
extracellular domain. 
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From centromere to telomere: LOC107986108, 
LOC105374023, ALCAM, CBLB, LOC107986109, 
LOC105374024 
Local order of ALCAM is shown together with leading and subsequent genes on chromosome 3. The direction 
of arrows indicates transcriptional direction on the chromosome and arrow sizes approximate gene sizes. 
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Exons are shown as boxes, introns are shown as lines. 
Description 
ALCAM gene is 210,200 bp long and resides on the 
positive strand on DNA. The gene has a total of 16 
exons. 
Transcription 
ALCAM gene codes for 9 transcripts, 4 of them are 
protein coding (4701, 4189, 2496, 1818 bp) and 5 of 
them are non-protein coding transcripts (2845, 1770, 
1242, 783, 564 bp). 
Pseudogene 
No reported pseudogenes for ALCAM. 
Protein 
Note 
ALCAM is a glycoprotein of the immunoglobulin 
superfamily and has an estimated molecular weight 
of 100-105 kDa. 
 
Domains are shown as bars. 
Expression 
ALCAM is expressed in almost every tissue. Higher 
expression is observed in parathyroid gland. Tissues 
with medium ALCAM expression are cerebral 
cortex, cerebellum, thyroid gland, tonsil, 
nasopharynx, bronchus, lung, liver, gallbladder, 
pancreas, salivary gland, stomach, urinary bladder, 
kidney, epididymis, prostate, seminal vesicle, breast, 
cervix, uterine, endometrium and fallopian tube. 
Tissues with low expression are hippocampus, 
caudate, adrenal gland, appendix, lymph node, oral 
mucosa, rectum, duodenum, small intestine, colon, 
ovary, placenta, soft tissue and skin. Spleen, bone 
marrow, heart muscle, smooth muscle, skeletal 
muscle, esophagus, testis, vagina and adipose tissue 
have no ALCAM expression (The Human Protein 
Atlas, http://www.proteinatlas.org/). 
Localisation 
ALCAM protein is localized to the cell membrane 
(Bowen et al., 1995). 
Function 
ALCAM is a type-I transmembrane protein, which 
belongs to the immunoglobulin superfamily (Bowen 
et al., 1995). It constitutes 5 immunoglobulin-like 
domains and a short COOH-terminal cytoplasmic 
tail (Weidle et al., 2010). ALCAM was first shown 
as a ligand of CD6 on activated leukocytes (Whitney 
et al., 1995). Then, it was found on hematopoietic 
stem cells and myeloid progenitors (Swart, 2002). 
ALCAM-CD6 interaction mediates T-cell activation 
or proliferation. In addition, ALCAM-ALCAM 
homophilic interaction contributes to cellular 
changes, such as angiogenesis, immune response and 
cell migration during the neuronal development (van 
Kempen et al., 2001). The expression of ALCAM 
was found during organ development in the central 
and peripheral nervous system, sensory organs, 
hematopoiesis, endothelial and epithelial lineage 
(Swart, 2002). Furthermore, a short ALCAM 
transcript leads to a soluble isoform of ALCAM 
(sALCAM). This isoform has only one 
immunoglobulin-like domain (D1), which is 
important for ligand binding (Ikeda and 
Quertermous, 2004). The roles of sALCAM were 
considered to block hemophilic binding of ALCAM 
and endogenous ALCAM function (Swart, 2002). 
Moreover, sALCAM was also shown to inhibit 
tumor progression in melanoma cells (van Kilsdonk 
et al., 2008). 
Mutations 
Note 
There are only a few reported mutations in ALCAM. 
One of the known cases is the deletion of ALCAM 
at 3q13.1 in a keratocystic odontogenic tumor. This 
mutation is thought to contribute to a matrix 
metalloproteinase-mediated proteolytic cascade, 
leading to tumor growth (Heikinheimo et al., 2007). 
In addition, it was reported that deletion of ALCAM 
might be related to craniofacial abnormalities 
(Simovich et al., 2008). 
Epigenetics 
ALCAM promoter contains several cis-acting 
elements including RELA  (p65 NF-kB) binding 
motif. This motif has several CpG residues and it is 
highly methylated in breast cancer cells, resulting 
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with loss of ALCAM expression (King et al., 2010). 
Hypermethylation of ALCAM promoter was also 
observed in preeclampsia placentas (Yeung et al., 
2016). 
Implicated in 
Acute Myeloid Leukemia (AML) 
CD166/ALCAM protein levels were reported to be 
significantly upregulated in AML cell lines and 
AML blasts of some patients (Strassberger et.al., 
2014). 
Brain Tumors 
ALCAM was reported to be enriched in brain tumor 
cells to promote invasion (Kijima et.al., 2012). It was 
suggested that ALCAM/ALCAM interaction may 
play an important role in early stages of metastasis 
seeding in the brain (Soto et.al., 2014). 
Breast Cancer 
Loss of ALCAM expression was found to increase 
the invasiveness of breast cancer cells and reduced 
levels of ALCAM was associated with poor 
prognosis. ALCAM overexpression caused cell 
growth reduction and a decrease in adhesion to 
matrix and migration. Low levels of ALCAM in 
breast cancer cells have been linked to bone matrix 
adhesion, which leads to bone metastasis (Davies S. 
and Jiang W.G., 2010). It was suggested that high 
ALCAM levels were seen in normal and cancerous 
breast epithelial cells and loss of ALCAM 
expression is associated with tumor progression, 
accelerated cell proliferation and decrease in 
survival (Brandt et.al., 2014). Furthermore, low 
expression of ALCAM contributes to a more 
aggressive phenotype among African-American 
women (Tan et.al., 2014). Interestingly, elevated 
serum levels of ALCAM was found to be correlated 
with aggressive tumor behavior in breast cancer 
patients indicating that serum ALCAM may be used 
as a biomarker (Witzel et.al., 2012). 
Chordoma 
ALCAM is a positive biomarker for chordoma and 
might play an important role for chordoma relapse 
(Chen et.al., 2015). 
Cholangiocarcinoma 
ALCAM protein is expressed on the membranes of 
invasive Cholangiocarcinoma cells so that might be 
used as a biomarker for diagnosis, prognosis and 
therapy (Adisakwattana et.al., 2015). 
Endometrial Cancer 
ALCAM is an early stage endometrioid endometrial 
cancer biomarker and important in regulation of cell 
migration, invasion and metastasis of endometrial 
cancer (Devis et.al., 2016). 
Gall Bladder Cancer 
SNPs within ALCAM (ALCAM rs1157G>A) gene, 
may play a role in GBC susceptibility (Yadav et.al., 
2015). 
Gastric Cancer 
Elevated levels of miR-9 may lead to ALCAM 
mRNA level reduction in SGC-7901 human gastric 
cancer cells (Ye et.al., 2004). 
Colorectal Cancer 
PROM1 (CD133) and ALCAM co-localization is 
seen during early stages of colon tumorigenesis, 
indicating well differentiation (Margaritescu et.al., 
2014). ALCAM expression was detected in colon 
CSCs in humans and also in premalignant 
adenomatous polyps (Leavell et.al., 2012). 
Difference in cellular location of ALCAM cause 
differences in prognostic value and cytoplasmic 
expression is associated with worse prognosis 
outcome and CD166 expression of it, is an indicator 
of advanced T category and N-positive status in 
colorectal cancer (Ni et.al., 2013). 
Liver Cancer 
ALCAM and CD44 promote tumorigenesis of liver 
cells and might be important for therapy strategies 
(Ma et.al., 2014). It was also shown that the 
ALCAM/AKT axis regulates tumorigenesis by post-
translational modifications and cytosolic 
accumulation of FOXO proteins in hepatoma cells 
(Yu et.al., 2014). 
Lung Cancer 
ALCAM was reported to be overexpressed in small 
cell lung cancers (Teicher A.B., 2014). 
Overexpression of ALCAM leads to malignancy in 
non-small cell lung carcinomas (NSCLC) (Ishiguro 
et.al., 2013). ALCAM expression levels were 
associated with smaller tumors with no lymph node 
metastasis in primary NSCLC lesions (Tachezy 
et.al., 2014). 
Melanoma 
High levels of ALCAM expression in primary 
tumors indicate poor prognosis and invasive 
phenotype (Donizy et.al., 2015). 
Mesothelioma 
ALCAM, was detected as one of the most highly 
upregulated genes in all 20 cell lines of 
Mesothelioma which may indicate that ALCAM 
overexpression is associated with tumor progression 
and ALCAM may be a target for treatment  (Ishiguro 
et.al., 2012). 
Myeloma 
It was reported that ALCAM is associated with cell 
migration and invasion in myeloma cell lines (NCI-
H929, JJN3, KMS-11, MM1S, OPM2, RPMI-8226, 
U266, and U266-LR7 (Paiva et.al., 2015). 
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Nasopharyngeal Carcinoma 
ALCAM is a positive marker of Cancer Stem Cells 
and expressed in nasopharyngeal carcinoma cells 
(Chen et.al., 2015). 
Ovarian Cancer 
ALCAM levels are associated with progression-free 
survival in ovarian cancer cells as a MIR378A target 
(Chan et.al., 2014). EGFR was found to control the 
release of ALCAM from ovarian cancer cells via a 
metalloproteinase associated mechanism (Lozneanu 
et.al., 2015). Serum sALCAM levels were found to 
be significantly higher in epithelial ovarian cancer 
(EOC) compared to controls and elevated serum 
levels of sALCAM were associated with MUC16 
(CA125) level and more aggressive (type II) tumors 
(Carbotti et.al., 2013). It was shown that ALCAM is 
expressed at the surface of epithelial ovarian cancer 
(EOC) cells and may be internalized after soluble 
ligand engagement (Nuti et.al., 2013). 
Pancreatic Cancer 
ALCAM is expressed in most of the pancreatic 
cancer lesions, but there is not any association 
between clinical and pathological data (Tachezy 
et.al., 2012). ALCAM expressing (CD166+) 
pancreatic cancer cells are reported to be strongly 
tumorigenic, but interestingly, CD166- pancreatic 
cancer cells show stronger invasive and migratory 
activities. (Fujiwara et. al., 2014). ALCAM levels 
are upregulated in Pancreatic Stellate Cells of 
pancreatic cancer tissues, which may indicate a role 
for ALCAM to regulate pancreatic cancer cell-
pancreatic stellate cell interaction (Zhang et.al., 
2016). 
Rectal Cancer 
It was found that ALCAM expression is upregulated 
after radiochemotherapy compared to pre-treatment 
stage in rectal cancer patients, indicating that 
radiochemotherapy upregulates stem cell markers in 
patients with rectal cancer (Deng et.al., 2014).   
Salivary Gland Tumor 
ALCAM is overexpressed in both benign and 
malignant salivary gland tumors. ALCAM 
expression is associated with more aggressive 
behavior in malignant tumors (Andisheh-Tadbir 
et.al., 2015). 
Thyroid Carcinoma 
Elevated levels of ALCAM are associated with 
aggressive tumors and lymph node metastasis of 
thyroid carcinoma Chaker et.al., 2013). 
Other diseases 
Higher ALCAM expression reported in other cases 
are listed below:  
 Dental follicles in children (Kang et al., 2016) 
 Lymphocytes infected with human T-lymphotropic 
virus type 1 (Curis et al., 2016) 
 Scrub typhus patients (Otterdal et al., 2014) 
 Salivary gland epithelial cells of Sjögren's 
syndrome patients  (Le Dantec et al., 2013) 
 Subcutaneous abdominal adipose tissue of male 
obese patients  (Gonzalez-Muniesa et al., 2013) 
 Human immunodeficiency virus (HIV)-infected 
patients with diapedesis compared to HIV 
seronegative (Williams et al., 2014) 
 The urine of Type I diabetes patients (Suh et al., 
2015)  
 
ALCAM has been implicated in various pathologies 
other than cancer. For example, multiple sclerosis is 
speculated to be associated with genetic variations of 
ALCAM. (Wagner et al., 2013, Wagner et al., 2014).  
 
Elevated ALCAM expression could increase the 
recruitment of leukocytes into the microvasculature, 
leading to atherosclerosis (Zimmerman et al., 2006). 
Another study reported that ALCAM could promote 
heart injury (Lolyeva et. al., 2013).  
 
Higher ALCAM concentrations in plasma of people 
with acute ischemic stroke have lower survival rate 
(Smedbakken et al., 2011).  
 
Single nucleotide polymorphisms (SNPs) in 
ALCAM were associated with active adult-onset 
nonallergic asthma, Crohn's disease, rheumatoid 
arthritis and type I diabetes (Siroux et al., 2014, 
Eleftherohorinou et al.,, 2009). 
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